Skip to main content

Racial and Socioeconomic Disparities in the CLL Community Oncology Setting With Ira Zackon, MD

Oncology Data Advisor® · Racial and Socioeconomic Disparities in the CLL Community Oncology Setting: Ira Zackon, MD At the recent 2023 American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor sat down with Ira Zackon, MD, a Senior Medical Director with Ontada, to discuss his abstract and presentation about racial and socioeconomic disparities experienced by patients in the chronic lymphocytic leukemia (CLL) community oncology and hematology setting, how to comba...

Continue reading

Investigating Hypomethylating Agents for Myelodysplastic Syndromes With Amer Zeidan, MBBS, MHS

Recently, at the American Society of Hematology (ASH) Annual Meeting, Amer Zeidan, MBBS, MHS, the Interim Chief of Hematologic Malignancies Division at the Yale Cancer Center, presented his abstract regarding an investigation of oral decitabine and cedazuridine versus intravenous/subcutaneous hypomethylating agents (HMA) for patients with myelodysplastic syndromes (MDS). In this interview, Dr. Zeidan further delves into his research and what it could mean for the future treatment landscape of MD...

Continue reading

Lowering Talquetamab Dosing Intensity to Improve Tolerability With Ajai Chari, MD

Oncology Data Advisor® · Lowering Talquetamab Dosing Intensity to Improve Tolerability: Ajai Chari, MD At the recent American Society of Hematology (ASH) Annual Meeting, Ajai Chari, MD, Director of the Myeloma Program at the University of California, San Francisco, sat down with Oncology Data Advisor to discuss his abstract and presentation regarding updated results from the MonumenTAL-1 study and what to look forward to from the ever-evolving treatment landscape of multiple myeloma. ...

Continue reading

Investigating Hypomethylating Agents for Myelodysplastic Syndromes With Amer Zeidan, MBBS, MHS

Oncology Data Advisor® · Investigating Hypomethylating Agents for Myelodysplastic Syndromes With Amer Zeidan Recently, at the American Society of Hematology (ASH) Annual Meeting, Amer Zeidan, MBBS, MHS, the Interim Chief of Hematologic Malignancies Division at the Yale Cancer Center, presented his abstract regarding an investigation of oral decitabine and cedazuridine versus intravenous/subcutaneous hypomethylating agents (HMA) for patients with myelodysplastic syndromes (MDS). In thi...

Continue reading